Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
41.71
+0.28 (+0.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,332,952
Open
41.50
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
41.43
Today's Range
41.34 - 41.80
52wk Range
29.20 - 41.80
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter
August 19, 2024
The company reported a surprise profit in the second quarter, vs. expectations for losses.
Via
Investor's Business Daily
Performance
YTD
+14.75%
+14.75%
1 Month
+5.43%
+5.43%
3 Month
+33.26%
+33.26%
6 Month
+28.26%
+28.26%
1 Year
+13.71%
+13.71%
More News
Read More
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
August 18, 2024
Via
The Motley Fool
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
August 16, 2024
Via
Benzinga
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
August 15, 2024
Via
Benzinga
Exposures
Product Safety
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
August 15, 2024
Via
The Motley Fool
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
August 13, 2024
Via
Benzinga
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
August 08, 2024
Via
Benzinga
Here's Why Eli Lilly Stock Dropped 12% Last Month
August 08, 2024
Via
The Motley Fool
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
August 07, 2024
Via
Benzinga
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
August 05, 2024
Via
Benzinga
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
August 02, 2024
Via
The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
July 29, 2024
Via
The Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
July 24, 2024
Via
Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
July 23, 2024
Via
The Motley Fool
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
July 22, 2024
Via
Benzinga
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
July 22, 2024
Via
The Motley Fool
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
July 22, 2024
Via
The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
Via
Investor's Business Daily
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
Via
Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
July 18, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
July 18, 2024
From
Genentech
Via
Business Wire
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
July 17, 2024
Via
The Motley Fool
Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study
July 17, 2024
From
Genentech
Via
Business Wire
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
July 17, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.